Tian Zhang, MD, MHS, UT Southwestern Medical Center

Articles

Non-metastatic Castration-Resistant Prostate Cancer: Patient Monitoring Strategies

April 12th 2023

Experts on non-metastatic castration-resistant prostate cancer share insight on patient monitoring strategies to improve outcomes.

Importance of Quality of Life When Choosing Therapy for nmCRPC

April 5th 2023

A brief discussion on the role of quality of life in selecting best therapy for patients with non-metastatic castration-resistant prostate cancer.

AR Inhibitors in nmCRPC: Real-World Data

April 5th 2023

Key opinion leaders reflect on the real-world use and data behind AR inhibitors in non-metastatic castration-resistant prostate cancer.

nmCRPC: Clinical Trial Data on AR Inhibitors

March 29th 2023

Shared insight on the SPARTAN, PROSPER, and ARAMIS studies with androgen receptor (AR) inhibitors in non-metastatic castration-resistant prostate cancer.

Goals of Treatment for Non-metastatic Castration-Resistant Prostate Cancer

March 29th 2023

Expert oncologists provide a focused review on goals of therapy for patients with non-metastatic castration-resistant prostate cancer (nmCRPC).

Key Unmet Needs in Prostate Cancer Management

March 22nd 2023

Before centering discussion on subsets of prostate cancer, panelists consider general challenges and unmet needs within the treatment landscape.

Recent Progress in the Prostate Cancer Treatment Landscape

March 22nd 2023

Key opinion leaders provide a broad perspective on recent shifts in the treatment landscape for prostate cancer.

Dr. Zhang on Key Phase 3 Trials for PARP Inhibitors in mCRPC

March 8th 2023

Tian Zhang, MD, MHS, discusses key phase 3 trials evaluating PARP inhibitors in the treatment of metastatic castration-resistance prostate cancer.

Prostate Cancer Imaging: Unmet Needs and Knowledge Gaps

March 3rd 2023

Medical oncologist Tian Zhang, MD, outlines the remaining unmet needs and knowledge gaps surrounding imaging of prostate cancer.

Breakthroughs in Imaging Modalities for Prostate Cancer

March 3rd 2023

Five expert panelists in prostate cancer consider how recent advances in imaging, particularly PSMA-PET, have impacted the field, and highlight guidelines that may aid clinicians in selecting amongst the available imaging modalities.

Dr. Zhang on the Use of PARP Inhibitor–based Combinations in mCRPC

February 21st 2023

Tian Zhang, MD, MHS, discusses the use of PARP inhibitor–based combinations in patients with metastatic castration-resistant prostate cancer.

Dr. Zhang on the EV-302 Trial in Metastatic Urothelial Cancer

January 16th 2023

Tian Zhang, MD, discusses the investigation of the combination of enfortumab vedotin plus pembrolizumab in the phase 3 EV-302 trial in the frontline setting for metastatic urothelial cancer.

Dr. Zhang on Multidisciplinary Approaches in Urothelial Cancer

September 30th 2022

Tian Zhang, MD, discusses the utilization of multidisciplinary approaches in urothelial cancers.

Dr. Zhang on the Key Objectives of the PDIGREE Trial in Advanced RCC

October 8th 2021

Tian Zhang, MD, discusses the ongoing phase 3 PDIGREE trial, evaluating the combination ipilimumab plus nivolumab, followed by nivolumab with or without cabozantinib, in patients with advanced renal cell cancer.

Rapid Readouts: ODENZA trial

October 7th 2021

Dr Zhang, MD, discusses cognitive assessment data from patients with metastatic castrate-resistant prostate cancer in the ODENZA trial receiving either darolutamide or enzalutamide that was presented at the European Society for Medical Oncology 2021 Annual Meeting.

Dr. Zhang on Emerging Biomarkers of Response to Immunotherapy in RCC

March 1st 2021

Tian Zhang, MD, discusses emerging biomarkers that are helping to guide treatment for patients with renal cell carcinoma.

Dr. Zhang on the PDIGREE Trial Examining Nivolumab/Ipilimumab Plus Cabozantinib in Metastatic RCC

February 11th 2021

Tian Zhang, MD, discusses the goal of the ongoing PDIGREE trial examining nivolumab and ipilimumab plus cabozantinib in patients with metastatic untreated renal cell cancer.

Dr. Zhang on the Combination of LAG525 and Spartalizumab in Advanced Malignancies

November 12th 2020

Tian Zhang, MD, discusses the combination of ieramilimab and spartalizumab in advanced malignancies.

Dr. Zhang on the IMvigor130 Trial in Metastatic Urothelial Cancer

October 12th 2019

Tian Zhang, MD, discusses data from the randomized phase III IMvigor130 trial, which compared the safety and efficacy of atezolizumab in combination with platinum-based chemotherapy, atezolizumab monotherapy, and chemotherapy alone, in the frontline treatment of patients with metastatic urothelial cancer.

Dr. Zhang Discusses Neoadjuvant Therapy in Kidney Cancer

January 25th 2018

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses neoadjuvant therapy in kidney cancer.